网友提问:
亿帆医药(002019)
HENDERSON, Nev.--(BUSINESS WIRE)--Jun. 25, 2018-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday, June 29th at 8:30 a.m. EDT/5:30 a.m. PDT to discuss the ROLONTIS Phase 3 ADVANCE study data being presented at Multinational Association of Supportive Care in Cancer (MASCC) 2018 annual meeting. The call will feature a presentation from ADVANCE study lead investigator, Lee S. Schwartzberg, M.D., FACP
网友回复
做人赁良心:
大学生呢
MAY0803:
LROONTIS®(EFLAPEGASTIM)第3阶段超前研究数据
亨德森,Nev. -(美国商业资讯)- 2018年6月25日-波谱制药(NASDAQGS:SPPI),生物技术公司,与血液和肿瘤的主要集中在商业和药物开发业务,今天宣布,该公司将在星期五,J召开电话会议。UNE第二十九上午8点30分EDT/5:30上午PDT讨论LRONTIS阶段3提前研究数据在多国癌症支持服务协会(MASCC)2018年会上提交。该呼叫将由高级研究带头人、M.D. Lee S. Schwartzberg、FACE医学教授和分部主任、田纳西大学血液学肿瘤学教授、HEH科学中心和UT/Western癌症中心执行主任介绍。。。。